Kemagel Biopharma Rebrands as Lerna Bio and Files IPO Prospectus

On September 27, CARGENE BIOPHARMA officially announced its renaming to "CARGENE BIOPHARMA." This change reflects the company's unwavering commitment to achieving groundbreaking innovations in drug development by fully leveraging RNA technology and breakthrough biological insights in the field of liver regeneration.

"The name 'CARGENE' originates from a legendary lake in ancient Greek mythology, renowned for its exceptional healing powers. Ms. He Qizhi, CEO of CARGENE BIOPHARMA, stated: 'The renaming of the company to CARGENE BIOPHARMA represents our ambitious goal to redefine treatments for advanced liver diseases and other conditions. This name symbolizes healing, innovation, and purpose. CARGENE is more than just a name; it embodies our vision for the future and the company’s core mission: to cure diseases and improve lives through cutting-edge biopharmaceutical solutions.'"

We are passionate about this new chapter of the company and look forward to sharing this hopeful journey with you. The combination of regenerative science and RNA technology will revolutionize the landscape of the pharmaceutical field, creating an entirely new future.

About CARGENE BIOPHARMA

CARGENE BIOPHARMA is a small nucleic acid drug research and development company that focuses on fully leveraging the liver's intrinsic regenerative potential to provide innovative solutions for patients with limited treatment options. Our innovation originates from Dr. Torsten Wuestefeld's QuartzTM target identification platform, a versatile in vivo functional genomic screening platform capable of generating a series of potential targets for liver diseases and other conditions. Our lead program is a first-in-class GalNAc-siRNA, which improves liver function in patients with cirrhosis by promoting liver regeneration.